NATURAL HISTORY AND TREATMENT OF CHRONIC NON-A, NON-B HEPATITIS

慢性非甲、非乙型肝炎的自然史和治疗

• 批准号: 3855407
• 负责人: E A JONES
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3855407
• 关键词: antiviral agents; chronic disease /disorder; clinical trials; dosage; hepatitis C virus; human subject; human therapy evaluation; human tissue; interferons; liver disorder chemotherapy; liver pharmacology; longitudinal human study; microorganism disease chemotherapy; pathologic process; ribavirin; serology /serodiagnosis; transaminases; virus RNA

Patients with well-documented chronic non-A, non-B hepatitis are being evaluated to determine the long-term natural history of this common form of chronic liver disease. A cohort of such patients are available to evaluate experimental therapies. Previous studies have shown that alpha interferon therapy has a short-term beneficial effect in approximately 50% of patients during treatment and that the beneficial response is sustained in approximately 20% after stopping interferon. A pilot study of ribavirin therapy has been conducted in 14 patients with chronic hepatitis C. Serum aminotransferases decreased during therapy in all patients and became normal in 5 (36%). Serum levels of HCV RNA also decreased significantly during therapy.

患有有据可查的慢性非甲型、非乙型肝炎的患者正在接受治疗 进行评估以确定这种常见形式的长期自然史 慢性肝病。 一组此类患者可用于评估 实验疗法。 先前的研究表明，α干扰素 治疗对大约 50% 的患者有短期有益效果 在治疗期间，并且有益反应持续存在 停止干扰素后约20%。 利巴韦林的初步研究 对14名慢性丙型肝炎患者进行了治疗。 血清 所有患者的转氨酶在治疗期间均下降，并变为 5 例（36%）正常。 血清HCV RNA水平也显着下降 治疗期间。